<DOC>
	<DOCNO>NCT00197431</DOCNO>
	<brief_summary>S-1 novel oral fluorouracil antitumor drug consist tegafur prodrug 5-fluorouracil ( 5-FU ) ; 5-chloro-2,4-dihydropyridine ( CDHP ) , inhibit dihydropyrimidine dehydrogenase ( DPD ) activity ; potassium oxonate ( Oxo ) , reduce gastrointestinal toxicity . 5-FU metabolized CYP2A6 DPD . In study , researcher investigate influence difference activity CYP2A6 DPD pharmacokinetics pharmacodynamics S-1 clinical outcome digestive organ cancer patient treat S-1 .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study S-1 Patients With Digestive Organ Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Patients digestive organ cancer Patients without digestive organ cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2003</verification_date>
</DOC>